E-VERSLO VARTAI, UAB - financials and debts

Company age: 2 y. 10 mo.

Update

E-VERSLO VARTAI - Company finances

EUR
2023
From: 2023-11-06
To: 2023-12-31
2024
From: 2024-01-01
To: 2024-12-31
2025
From: 2025-01-01
To: 2025-12-31
Financial data
Sales revenue - 2,676,041 4,009,941
Profit before tax -50 58,103 21,016
Net profit -50 49,388 17,653
Equity 2,450 51,838 69,491
Liabilities 100 118,585 182,779
Non-current assets 0 0 21,000
Current assets 2,550 170,423 231,270
Total assets 2,550 170,423 252,270
Taxes paid
STI taxes - 96,741 153,175
Financial indicators
Revenue change y/y - - +49.8%
ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. -2.0% 29.0% 7.0%
ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. -2.0% 95.3% 25.4%
Profit margin Net profit margin. Shows the overall profitability of the company. - 1.8% 0.4%
EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. - 2.2% 0.5%
Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. 0.0 2.3 2.6
Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. - 1,338,021 2,405,916

Purchase full financial statements

Profit/Loss, Balance Sheet, Cash Flow, Equity

9.99 € + PVM Buy

See Scoris data in Google Search

Mark Scoris as a favorite source. One click, no registration.

E-VERSLO VARTAI - Social security debts

The company had no debts to Sodra

E-VERSLO VARTAI - VMI tax arrears

From To Overdue, €
2026-04-13 2026-04-13 15.36
2025-10-30 2025-11-24 1.2
2025-09-26 2025-10-22 1.2
2025-04-28 2025-05-20 4.25
2025-03-28 2025-04-24 4.25

VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.

Analysis of the company's financial position

This description was generated by artificial intelligence. Report if inaccurate.
E-VERSLO VARTAI, UAB (code 306621337) is a Private Limited Liability Company engaged in the retail sale of pharmaceutical products. In 2025, the company generated revenue of €4.01M, up 49.9% year on year from €2.68M in 2024. Net profit decreased to €17.7K from €49.4K, and the profit margin narrowed to 0.4% from 1.8% a year earlier, indicating that growth in turnover was accompanied by weaker profitability. The short 2023 period ended with a net loss of €50. The balance sheet expanded in 2025 to €252.3K in total assets, supported by €69.5K in equity and €182.8K in liabilities. Short-term assets accounted for €231.3K, while long-term assets were €21.0K. Reported ratios show a return on equity of 25.4%, return on assets of 7.0%, debt-to-equity of 2.63, and asset turnover of 15.90x. Revenue per employee was €4.01M and profit per employee was €17.7K, pointing to high operating intensity.